Pharmacokinetic study of osimertinib in NSCLC patients with body fluid

Pharmacokinetic study of osimertinib in NSCLC patients with body fluid - Pharmacokinetic study of osimertinib in NSCLC patients with body fluid

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028922

Enrollment

Registered

2017-09-15

Start date

2017-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmation of non small cell lung cancer 2) The history of EGFR-TKI therapies 3) Detected T790M mutation by rebiopsy samples 4) Administration of osimertinib is planned or ongoing 5) At least one or more measurable lesion by RESIST (Version1.1) (patients who have only pleural effusion are eligible) 6) Aged 20 or more 7) Written informed consent

Exclusion criteria

Exclusion criteria: Patients with interstitial pneumonitis identified by chest X-ray

Design outcomes

Primary

Measure	Time frame
The association of malignant effusion with osimertinib exposure in non-small cell lung cancer	—

Countries

Japan

Contacts

Public ContactTakahisa Kawamura/ Kenmotsu Hirotsugu

Shizuoka cancer center Devision of Thoracic Oncology

ta.kawamura@scchr.jp(+81)055-989-5222

Outcome results